Axial Biotherapeutics raises $19.15M to target gut-brain axis
Axial Biotherapeutics is the latest startup working to manipulate the microbiome as a means to treat disease. The Caltech spin-out just announced $19.15 million in Series A funding to tackle a range of central nervous system disorders.
